Expert Insights on GCT Cold Chain Logistics

71. Cryogenic Transport For Gene Therapy Products — The Pros And Cons 3/21/2019

    Temperature-controlled packages used for the transport of gene therapy products use a combination of thermal insulators or thermoregulators to decrease the heat transfer rate from outside of the shipper to the inside. In this two-part article, we will explore common methods of temperature-controlled transportation and delve into their pros and cons. In Part 1, we focus on passive cryogenic options.

72. Big Data And AI In Pharma Development And Manufacturing: An Inside Look 2/27/2019

    Artificial intelligence and Big Data have the potential to lower the cost and time of drug trials, to better determine patient outcomes with established drugs, and to better design new drugs.

73. Recalibrating The Supply Chain For Allogeneic Cell Therapies 2/25/2019

    In November 2018, I wrote an article about establishing a supply chain for autologous cell therapies — those formulated using a patient’s own cells. This partner piece highlights considerations that need to be taken into account when developing a commercialization and supply chain strategy for allogeneic cell therapies.

74. Critical Considerations For Packaging And Delivery Of Gene Therapy Products 12/20/2018

    The temperature-sensitivity of cell and gene therapies, their personalized nature, and their circular (“vein-to-vein”) supply chain make maintaining a seamless supply chain critical; however, it is not easily achieved.

75. Establishing A Critical Supply Chain For Autologous Cell And Gene Therapies 11/15/2018

    With the recent breakthroughs in cell and gene therapy, there is increased emphasis on the design and implementation of different supply chain models to support the movement of materials and drug product across the chain of care. Unlike more traditional supply chains, many of these therapies have unpredictable sources and manufacturing and infusion locations. The most extreme example is loosely referred to as the “vein-to-vein” supply chain — particularly for autologous therapies.

76. Environmental Risks & The Life Science Supply Chain: Lessons Learned From Hurricane Maria 1/15/2018

    Looking back at the hurricane season from the perspective of supply chain risk — and specifically risks that have impacted the life sciences supply chain — there are many lessons to be learned.

77. 5 Proven Steps To Successfully Select & Onboard Outsourced Logistics Partners 1/23/2017

    In preceding articles in this series, we reviewed some of the challenges and remediation approaches for the storage and distribution of life science products, highlighting some of the specific risks related to storage, transportation, and material control across an extended chain of custody. This brings us to the final article, in which we will discuss best practices for selecting the partners that will be an extension of your staff for monitoring and control across an ever-changing global landscape.